Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of Oral Metronomic Dosing of Oral Cyclophosphamide with Dexamethasone for Metastatic Castration Resistant Prostate Cancer

NCT05479578 is registered in ClinicalTrials.gov with Rashmi Verma, MD as lead sponsor.

NCT NCT05479578
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05479578 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of Oral Metronomic Dosing of Oral Cyclophosphamide with Dexamethasone for Metastatic Castration Resistant Prostate Cancer
Lead sponsor
Rashmi Verma, MD
Phase
Phase 1
Overall status
Active, not recruiting
Start date
June 29, 2022
Completion date
May 1, 2025
Enrollment
7 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

castration-resistant prostate carcinoma, metastatic prostate adenocarcinoma, stage ivb prostate cancer american joint committee on cancer (ajcc) v8